FOJTŮ, Michaela, Jan BALVAN, Tomáš VIČAR, Hana HOLCOVÁ POLANSKÁ, Barbora PELTANOVÁ, Stanislava MATEJKOVA, Martina RAUDENSKÁ, Jiri STURALA, Paula MAYORGA-BURREZO, Michal MASAŘÍK and Martin PUMERA. Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance. ACS APPLIED MATERIALS & INTERFACES. WASHINGTON: AMER CHEMICAL SOC, 2021, vol. 13, No 27, p. 31355-31370. ISSN 1944-8244. Available from: https://dx.doi.org/10.1021/acsami.0c20458.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance
Authors FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution), Tomáš VIČAR (203 Czech Republic, belonging to the institution), Hana HOLCOVÁ POLANSKÁ (203 Czech Republic, belonging to the institution), Barbora PELTANOVÁ (203 Czech Republic, belonging to the institution), Stanislava MATEJKOVA (203 Czech Republic), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Jiri STURALA (203 Czech Republic), Paula MAYORGA-BURREZO, Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and Martin PUMERA (203 Czech Republic, guarantor).
Edition ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2021, 1944-8244.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 21001 Nano-materials
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 10.383
RIV identification code RIV/00216224:14110/21:00120131
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1021/acsami.0c20458
UT WoS 000674333400004
Keywords in English 2D nanomaterials; silicene; polysiloxane; nanosheets; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance
Tags 14110515, 14110518, CF CELLIM, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/2/2022 12:48.
Abstract
The development of cancer resistance continues to represent a bottleneck of cancer therapy. It is one of the leading factors preventing drugs to exhibit their full therapeutic potential. Consequently, it reduces the efficacy of anticancer therapy and causes the survival rate of therapy-resistant patients to be far from satisfactory. Here, an emerging strategy for overcoming drug resistance is proposed employing a novel two-dimensional (2D) nanomaterial polysiloxane (PSX). We have reported on the synthesis of PSX nanosheets (PSX NSs) and proved that they have favorable properties for biomedical applications. PSX NSs evinced unprecedented cytocompatibility up to the concentration of 300 mu g/mL, while inducing very low level of red blood cell hemolysis and were found to be highly effective for anticancer drug binding. PSX NSs enhanced the efficacy of the anticancer drug doxorubicin (DOX) by around 27.8-43.4% on average and, interestingly, were found to be especially effective in the therapy of drug-resistant tumors, improving the effectiveness of up to 52%. Fluorescence microscopy revealed improved retention of DOX within the drug-resistant cells when bound on PSX NSs. DOX bound on the surface of PSX NSs, i.e., PSX@DOX, improved, in general, the DOX cytotoxicity in vitro. More importantly, PSX@DOX reduced the growth of DOX-resistant tumors in vivo with 3.5 times better average efficiency than the free drug. Altogether, this paper represents an introduction of a new 2D nanomaterial derived from silicane and pioneers its biomedical application. As advances in the field of material synthesis are rapidly progressing, novel 2D nanomaterials with improved properties are being synthesized and await thorough exploration. Our findings further provide a better understanding of the mechanisms involved in the cancer resistance and can promote the development of a precise cancer therapy.
Links
LM2018129, research and development projectName: Národní infrastruktura pro biologické a medicínské zobrazování Czech-BioImaging
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1246/2020, interní kód MUName: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Acronym: KAVASYKAMO)
Investor: Masaryk University
MUNI/A/1698/2020, interní kód MUName: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF)
Investor: Masaryk University
NU21-08-00407, research and development projectName: Funkční nanoroboti pro navigovanou kombinovanou nádorovou terapii
Investor: Ministry of Health of the CR, Subprogram 1 - standard
ROZV/28/LF17/2020, interní kód MUName: Magnetoboti pro fototermální a magnetotermální terapii nádorových onemocnění
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects
PrintDisplayed: 11/5/2024 07:20